Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Abstract: A nutrition formula milk powder for infants after congenital heart disease surgery or non-cardiac surgery and critically ill infants in intensive care. The nutrition formula milk powder has an energy to protein ratio of 55-60 kcal:3.0-4.0 g/100 ml.

Abstract: Preparation of a product comprising stromal vascular fraction cells includes washing human biological material comprising adipose in a container apparatus having an internal filter, which divides an internal containment volume of the container apparatus into a tissue retention volume on one side of the filter and a filtrate volume on an opposite side of the filter, and a mixing device with at least one rotatable mixing member disposed in the tissue retention volume. The washing includes operation of the mixing device to rotate the mixing member through the human biological material within the tissue retention volume, and the washing is followed by digesting washed material within the internal containment volume with added enzyme, centrifuging of the container apparatus to prepare a centrifuged pellet in the filtrate volume, selectively removing material of the pellet and preparing a product with a mixture of stromal vascular fraction cells of removed pellet material and an aqueous suspension liquid.

Abstract: The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment of skin.

Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. This application provides novel compositions and methods for treating various disorders or conditions that are associated with a dysfunctional intestinal microbiota. In particular, this application provides compositions and methods that can treat or cure gastrointestinal (GI) disorders such as Inflammatory Bowel Disease (IBD), including, for example, Crohn's Disease and ulcerative colitis.

Abstract: The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

Abstract: A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.

Abstract: The present invention relates to a recombinant plasma membrane-based vesicle, and more specifically to a recombinant plasma membrane-based vesicle comprising a VSV-G mutated protein in which histidine, the 162nd amino acid, has been substituted with arginine, and a pharmaceutical composition for treating cancer comprising the recombinant plasma membrane-based vesicle.

Abstract: Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone treatment to effectively reduce tumor burden, the method comprising administering an oncolytic chimeric poliovirus construct, or an oncolytic chimeric poliovirus construct and an immune checkpoint inhibitor, followed by reduction of the tumor. The method may further comprise administration of immune checkpoint inhibitor or oncolytic chimeric poliovirus construct following reduction of tumor. Kits for performing the methods are also provided.

Abstract: The present invention provides a novel IL-1? and/or IL-6 expression inhibitor and use thereof. The IL-1? and/or IL-6 expression inhibitor in accordance with an aspect of the present invention contains a component derived from alcoholic fermentation lees.

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace that has been co-fermented with a complex fungi, compounded as a tablet or formulated within a capsule. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of at least one part soluble dietary fiber to 30 parts insoluble dietary fiber, and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Abstract: The present disclosure provides a pharmaceutical composition comprising a first pharmaceutically active portion comprising one or more cannabinoids extracted from cannabis plant material; a second pharmaceutically active portion comprising glutathione extracted from cannabis plant material and optionally one or more excipients; wherein the molar ratio of the second pharmaceutically active portion to the first pharmaceutically active portion is at least 0.5:1. The present disclosure also provides a method of manufacturing a pharmaceutical composition comprising the steps of: extracting a first fraction containing one or more cannabinoids from a cannabis plant material using a polar solvent; extracting a second fraction containing from the glutathione from the same cannabis plant material using water; and drying and combining the first fraction and the second fraction to form the pharmaceutical composition.

Abstract: The present invention is a novel and enhanced co-fermentation product of hemp and Cannabis, in which 1 part shredded or divided hemp stems, leaves and flowers are admixed into a slurry with 2 parts water and the slurry is sterilized prior to inoculation with solid or liquid mycelium culture. After inoculation, fermentation takes place at 66-70 degrees F. for 14-28 days, followed by drying of the fermented admixture at 110-165 degrees F. for 24-48 hours, prior to co-minuting or powdering the dried end product for incorporation in oral dosage forms such as pressed tablets, manufactured capsules or powder or as an ingredient in functional foods. By following these method steps including the initial creation of the 2:1 aqueous:hemp slurry, both hemp and mushroom component conversions occur to an unexpected degree.

Abstract: The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: The present invention relates to a composition having an anti-glycation effect and an application thereof. The anti-glycation composition includes the following constituents in parts by mass: 0.1 to 5 parts of Osmanthus fragrans extract, 0.1 to 5 parts of Punica granatum extract and 0.1 to 2 part of Olea europaea extract, wherein in the Osmanthus fragrans extract, a mass content of polyphenol is more than or equal to 10%, and a mass content of verbascoside is more than or equal to 10%; in the Punica granatum extract, a mass content of polyphenol is more than or equal to 30%, and a mass content of punicalagin is more than or equal to 8%; and in the Olea europaea extract, a mass content of polyphenol is more than or equal to 10%, and a mass content of hydroxytyrosol is more than or equal to 3%.

Abstract: The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

Abstract: Disclosed are a Filipendula glaberrima alcoholic extract and solvent fractions fractionated therefrom or novel compounds 1 and 2 purely isolated from a Filipendula glaberrima ethyl acetate fraction that have an excellent inhibitory effect against HMG-CoA reductase activity, an excellent antioxidant effect and a remarkably excellent effect of suppressing the formation of foam cells in macrophages. Also, disclosed is a pharmaceutical composition or health food composition for treating, preventing and ameliorating vascular diseases, hypercholesterolemia, or heart diseases caused by hypercholesterolemia, or lowering blood cholesterol levels, containing, as active ingredients, the Filipendula glaberrima alcoholic extract and the solvent fractions or the novel compounds 1 and 2.

Abstract: The present invention relates to a pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases which include a flower extract of Daphne genkwa or fractions thereof as an active ingredient. The pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases are, not like extracts from stems and/or roots of Daphne genkwa, free from genotoxicity and have superior prophylactic or treatment effects against neurodegenerative diseases.

Abstract: Disclosed are topical wound healing compositions useful in the holistic treatment of a patient's wound, particularly diabetic wounds of the foot. Methods of using these formulations topically and in coordinated use with certain oral supplements to improve treatment is also disclosed. In particular, formulations may include one or more of: water, Aloe Barbadensis leaf juice, micro silver, L-Arginine, locust bean gum, and Manuka honey. The topical formulations may be in the form of a gel.

Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.

Abstract: The present invention relates to a method of treating cancer by administering allostatine in combination with a chemotherapeutic agent. The combination therapy provides improved therapeutic efficacy for treatment of solid tumors, including pancreatic cancer, colorectal cancer and ovarian cancer. Further provided herein is a pharmaceutical composition for use in the combination therapy.

Abstract: The present invention relates to a method of treating cancer by administering alloferon in combination with a microtubule-stabilizing agent. The combination therapy provides improved therapeutic efficacy for treatment of solid tumors, including pancreatic cancer. Further provided herein includes a pharmaceutical composition for use in the combination therapy.

Abstract: A composition is provided comprising an electrospun fiber having a surface with a biological adhesive moiety conjugated to the surface of the electrospun fiber. The biological adhesive moiety included in the composition can be a lectin such as griffithsin. The composition can further include an effective amount of an antiviral agent encapsulated by an electrospun fiber. Nanoparticles including a microbicide conjugated to the surface of the nanoparticle can also be included in the composition. Methods of treating a viral infection are also provided and include administering to a subject an effective amount of a composition comprising an electrospun fiber having a surface and a biological adhesive moiety conjugated to the surface of the electrospun fiber.

Abstract: The present application provides bio-mimetic formulations, including formulations that mimic mammalian amniotic membrane and/or fluid, but with optimized amounts and formulas of various recombinant peptides. These formulations are stable for extended periods and can be used in various treatment methods including wound healing.

Abstract: The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (I LI 3RA2) for prevention and/or treatment of fibrosis, an autoimmune disease and/or an inflammatory disease. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2 or a sequence variant thereof for prevention and/or treatment of fibrosis, an autoimmune disease and/or an inflammatory disease. Moreover, the present invention also provides an immunogenic compound, a nanoparticle and a pharmaceutical composition comprising such a (poly)peptide and a nucleic acid encoding such a (poly)peptide for use in prevention and/or treatment of fibrosis, an autoimmune disease and/or an inflammatory disease.

Abstract: Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.

Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fins-related tyrosine kinase 3 (Fltt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1 alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Abstract: The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunocompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock.

Abstract: Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 ?m which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.

Abstract: Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis.

Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.

Abstract: Disclosed herein are compositions and methods for use in treating hyperhidrosis.

Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating metabolic disorders and modulating metabolic processes using PM20D1 and N-lipidated amino acids.

Abstract: The present invention relates to a composition comprising, as an active ingredient, a fusion protein of a cell penetrating peptide and adenosine deaminase, wherein the composition can be efficiently used for treating severe complex immunodeficiency due to the increased cell permeability of adenosine deaminase.

Abstract: The present application relates to an anti-microbial system for use in the treatment of microbial infections or control of microbial contamination, which avoids the use of antibiotics. Such infections include mastitis, tuberculosis, cystic fibrosis and the contamination that may result from biofilm formation on medical devices.

Abstract: Methods comprising a step of administering, to a mammalian male subject, a composition comprising ?-lactalbumin for the treatment of male breast cancer.

Abstract: The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.

Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.

Abstract: Vaccine design, polycistronic vaccine constructs, compositions, and methods comprising nucleic acids (DNA, RNA), peptides, proteins and derivatives thereof, including cells and cell-lines, for enhanced antigen-specific vaccination.

Abstract: Disclosed herein is a recombinant Chlamydia-activated B cell (CAB) platform, vaccines, and methods of using the same. Disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to a recombinant polypeptide derived from a Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods to use a recombinant polypeptide derived from a Chlamydia spp. as an adjuvant for induction of enhanced humoral immunity against an unrelated antigen (e.g., humoral immunity against HIV antigen). Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.

Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.

Abstract: Described herein are methods of treating or preventing genital warts comprising administering to a subject a therapeutically effective amount of a vaccine against human papillomavirus (HPV) and reducing exposure of an area susceptible to genital warts to moisture, to non-neutrally electrically charged materials, or a combination thereof. Also described are kits or articles of manufacture for use in treating or preventing genital warts.

Abstract: Described herein are methods of treating or preventing plantar warts comprising administering to a subject a therapeutically effective amount of a vaccine against human papillomavirus (HPV) and reducing exposure of an area susceptible to plantar warts to moisture, to non-neutrally electrically charged materials, or a combination thereof. Also described are kits or articles of manufacture for use in treating or preventing plantar warts.

Abstract: A method for adapting an influenza virus to Vero cells is provided. The method comprises infecting Vero cells with the influenza virus, cultivating the infected Vero cells, harvesting influenza viruses of each passage, wherein infectious dose of the influenza viruses of one passage is greater than or equal to infectious dose of the influenza viruses of a previous passage. The present disclosure also relates to a composition. Said composition comprises polyriboinosinic acid-polyribocytidylic acid, at least one antibiotic or polyamide compound, at least one positive ion, influenza viruses and/or influenza antigens, wherein said influenza viruses and/or influenza antigens are acquired from Vero cell adapted influenza viruses.

Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

Abstract: Gene therapy based combination therapy for malignant pleural mesothelioma (“MPM”) that is resistant to or recurrent after chemotherapy employing a viral vector containing a human interferon transgene, followed by standard first- or second-line cytotoxic chemotherapy. Overall survival rate was significantly higher than historical controls in the second-line group.